News

The DR:EAM trial will evaluate topically delivered OTT166 eye drops in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR) with minimal vision loss.

The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

According to 4DMT, the Dose Expansion stage of the PRISM trial is a multicenter, randomized study designed to evaluate the safety and efficacy of 4D-150 at two different dose levels.

Harrow states that this transaction will grant US and Canadian commercial rights to six therapeutics, including two non-prescription brands.

The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee has linked Apellis’ pegcetacoplan injection (Syfovre) with a handful of cases of occlusive retinal vasculitis.

Eye drops developed by Columbia University researchers could prove to be a more effective and comfortable therapy for retinal vein occlusion (RVO).

Nominations for the 2023 awards will close July 31, 2023.

The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on July 31, 2023 in Seattle, Washington.

The machine learning model analyzes retinal images and associated data and recognizes specific features to identify individuals with mild cognitive impairment.

Tenpoint’s aim is to reverse vision loss by generating specialized ocular cell types, both ex vivo and in vivo.

Cognition Therapeutics has dosed the first participant in the phase 2 MAGNIFY study of CT1812. This oral therapy is being studied as a for geographic atrophy (GA) secondary to dry age-related macular edema (AMD).

Akari remains on track and plans to submit an IND application to the US FDA in the first half of 2024, and plans on starting clinical trials in the second half of 2024

R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery.

This partnership will allow IRIS to license AEYE Diagnostic Screening (AEYE-DS), an FDA-cleared AI technology for autonomous detection of diabetic retinopathy (DR).

Apellis has announced that seven abstracts will be presented at the American Society of Retina Specialists Annual Scientific Meeting including safety and efficacy data for the company’s pegcetacoplan injection for geographic atrophy (GA).

Vantage Surgical Solutions has acquired Ophthalmic Surgical Solutions (OSS). OSS is a Kansas-based company specializing in ophthalmic surgical equipment and services.

This certifies that the facility adheres to a comprehensive set of regulatory standards as set by the NABP to ensure safety of drugs and medical devices in the US.

While these complications are rare, they require prompt diagnosis and management to prevent serious visual morbidity.

The drug, known as XIPERE in the US, is used to treat uvietic macular edema and goes by the name Arcatus when licensed by Clearside Biomedical’s partner in China, Arctic Vision.

The 2023 41st annual meeting of the American Society of Retina Specialists (ASRS) will run from Thursday, July 27 to Tuesday, August 1 in Seattle, a city filled with sightseeing, museums, and great food to explore.

Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.

ASRS is an international, state-or-the-art event offering something for everyone: scientific papers, posters, panel discussions on controversial issues and techniques, award lectures, a Retina Case Conference, the 25th Annual Film Festival, international symposia, and subspecialty review courses.

Researchers found that better general health and ability to drive were each separately associated with significantly lower risk of death among individuals with AMD.

Naor is stepping down to pursue new opportunities and will be replaced by Kenneth Sall, MD who has been appointed as Opthea’s Senior Medical Advisor.

This allosteric tyrosine kinase (TYK2) inhibitor may help to treat the disregulation of TYK2 mediated pathways may also play an important role in conditions, including noninfectious uveitis.

This trial is testing tinlarebant, a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA).

The PHOTON study demonstrates the long-term efficacy and safety of this treatment for patients with DME.

Research has found a new approach that identifies high-risk infants, so that not all preemies need to undergo an invasive eye exam.

This investigational new drug application was cleared for the company’s phase I/II clinical trial.

A new study titled, “Prevalence of Diabetic Retinopathy in the US in 2021,” finds that almost 10 million people in the United States with diabetes have diabetic retinopathy.